Compare Lumentum (LITE) vs Nuvation Bio Inc. Class A Common Stock (NUVB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lumentum vs Nuvation Bio Inc. Class A Common Stock — how do they compare? Lumentum trades at $1,104 (market cap $94.99B), while Nuvation Bio Inc. Class A Common Stock trades at $4.99 (market cap $1.74B). The key difference: Lumentum is far larger — about 54.6× Nuvation Bio Inc. Class A Common Stock's market cap, and Nuvation Bio Inc. Class A Common Stock is more actively traded (9,289,619 versus 4,855,776). Which is the better fit depends on your goals — on Pluang, investors hold Lumentum for 4 Days and Nuvation Bio Inc. Class A Common Stock for 1 Days on average.
| LITE | NUVB | |
|---|---|---|
Market Cap | $94.99B | $1.74B |
Volume | 4,855,776 | 9,289,619 |
Sector | Technology | Health |
52-Week High | $1.13K | $9.54 |
52-Week Low | $149.61 | $3.41 |
Typical Hold Time | 4 Days | 1 Days |
Enterprise Value | $93.92B | $1.33B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lumentum
Lumentum develops photonic products, including optical components, transceivers, and lasers. Its technologies support data centers, communications networks, industrial manufacturing, and sensing applications.
Read more on LITE →About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →
